Elicera Therapeutics (ELIC) investor relations material

Executive summary

• Operating loss for Q1 2026 was SEK -5.1 million, an improvement from SEK -8.1 million year-over-year.

• Loss for the period was SEK -5.1 million, with EPS at SEK -0.10, compared to SEK -0.22 in Q1 2025.

• Cash flow from operating activities was SEK -7.0 million, down from SEK -0.7 million in Q1 2025.

• Clinical progress included promising results in the CARMA study (ELC-301) and completion of a Phase I/IIa trial for ELC-100.

• Key personnel received prestigious awards, and a Japanese patent was granted for ELC-401.

Financial highlights

• Operating result improved by SEK 2.95 million year-over-year, mainly due to lower grants and higher costs.

• Cash and cash equivalents at period end were SEK 17.9 million, down from SEK 45.7 million a year earlier.

• Equity at period end was SEK 18.3 million, compared to SEK 32.8 million in Q1 2025.

• No investments or financing inflows during the quarter; cash flow for the period was negative SEK 7.0 million.

Outlook and guidance

• Preparations for ELC-401 clinical trial are ongoing, with first patient treatment targeted for 2027.

• Further updates from the CARMA study (ELC-301) are expected during 2026.

• Evaluation of next steps for ELC-100, including potential out-licensing, is underway.